title: Repeated albumin infusions do not lower blood pressure in preeclampsia.
abstract: Since intravascular volume contraction is regarded as an important pathological feature in preeclampsia, it has been proposed that plasma volume expansion could be a therapeutic manoeuver that interrupts the pathogenetic chain of hypovolemia inducing increased vascular resistance. Furthermore, tissue perfusion should be improved and, if albumin is used as plasma expander agent, interstitial edema should also be reduced. We report the results observed in an open pilot study in ten preeclamptic patients treated with daily albumin infusions (0.4 to 1 g/kg) from 7 to 36 days. No acute effects were shown on blood pressure, and the need for antihypertensive therapies did not decrease in the following days. Serial evaluation after at least five or ten days of repeated albumin infusions did not show stable changes in electrolytes excretion, renal clearances, serum protein concentration and hematocrit value, nor in aldosterone, renin and atrial natriuretic peptide basal levels, while proteinuria tended to increase. Uteroplacental and fetoplacental blood flow acutely ameliorated in 3 cases only after albumin 1 g/Kg, but reached basal values again on the next day. The clinical implications are that daily albumin infusions with this schedule dosage do not lower blood pressure and that they are unable to induce stable changes in renal function, uteroplacental and fetoplacental resistance. No maternal complications were observed during the conservative management, but fetal mortality was high (6/10). Given the uncontrolled study, we cannot know whether similar results had been achieved by conventional therapy only.
authors.affiliation: Department of Nephrology, University of Torino, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Stratta
authors.forename: C
authors.initials: C
authors.lastname: Canavese
authors.forename: M
authors.initials: M
authors.lastname: Dogliani
authors.forename: L
authors.initials: L
authors.lastname: Gurioli
authors.forename: M C
authors.initials: MC
authors.lastname: Porcu
authors.forename: T
authors.initials: T
authors.lastname: Todros
authors.forename: O
authors.initials: O
authors.lastname: Fianchino
authors.forename: C
authors.initials: C
authors.lastname: Benedetto
authors.forename: M
authors.initials: M
authors.lastname: Massobrio
authors.forename: L
authors.initials: L
authors.lastname: Balbi
mesh_terms: D000328:Adult; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001794:Blood Pressure / Q000502:physiology*; D005260:Female; D006801:Humans; D010865:Pilot Projects; D010952:Plasma Substitutes / Q000627:therapeutic use*; D011225:Pre-Eclampsia / Q000503:physiopathology / Q000628:therapy*; D011247:Pregnancy; D011256:Pregnancy Outcome / Q000453:epidemiology; D012709:Serum Albumin / Q000627:therapeutic use*
chemical_list: D000959:Antihypertensive Agents; D010952:Plasma Substitutes; D012709:Serum Albumin